nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CDC42BPB—uterine cervix—fallopian tube cancer	0.0166	0.0166	CbGeAlD
Nilotinib—MAPK8—epithelium—fallopian tube cancer	0.0151	0.0151	CbGeAlD
Nilotinib—MAPK8—uterine cervix—fallopian tube cancer	0.015	0.015	CbGeAlD
Nilotinib—FRK—female reproductive system—fallopian tube cancer	0.0147	0.0147	CbGeAlD
Nilotinib—CDC42BPB—uterus—fallopian tube cancer	0.0138	0.0138	CbGeAlD
Nilotinib—TIE1—epithelium—fallopian tube cancer	0.0131	0.0131	CbGeAlD
Nilotinib—TIE1—uterine cervix—fallopian tube cancer	0.013	0.013	CbGeAlD
Nilotinib—MAPK11—female reproductive system—fallopian tube cancer	0.0125	0.0125	CbGeAlD
Nilotinib—MAPK8—uterus—fallopian tube cancer	0.0125	0.0125	CbGeAlD
Nilotinib—CDC42BPB—female reproductive system—fallopian tube cancer	0.0124	0.0124	CbGeAlD
Nilotinib—EPHB3—uterine cervix—fallopian tube cancer	0.0124	0.0124	CbGeAlD
Nilotinib—MAPK11—female gonad—fallopian tube cancer	0.0114	0.0114	CbGeAlD
Nilotinib—HCK—uterine cervix—fallopian tube cancer	0.0114	0.0114	CbGeAlD
Nilotinib—CDC42BPB—female gonad—fallopian tube cancer	0.0113	0.0113	CbGeAlD
Nilotinib—BRAF—endometrium—fallopian tube cancer	0.0113	0.0113	CbGeAlD
Nilotinib—CDC42BPB—vagina—fallopian tube cancer	0.0112	0.0112	CbGeAlD
Nilotinib—MAPK8—female reproductive system—fallopian tube cancer	0.0112	0.0112	CbGeAlD
Nilotinib—EPHA6—female reproductive system—fallopian tube cancer	0.0112	0.0112	CbGeAlD
Nilotinib—EPHB3—endometrium—fallopian tube cancer	0.0112	0.0112	CbGeAlD
Nilotinib—TIE1—uterus—fallopian tube cancer	0.0108	0.0108	CbGeAlD
Nilotinib—BRAF—uterus—fallopian tube cancer	0.0104	0.0104	CbGeAlD
Nilotinib—EPHB3—uterus—fallopian tube cancer	0.0103	0.0103	CbGeAlD
Nilotinib—HCK—endometrium—fallopian tube cancer	0.0103	0.0103	CbGeAlD
Nilotinib—MAPK8—female gonad—fallopian tube cancer	0.0102	0.0102	CbGeAlD
Nilotinib—CA3—uterine cervix—fallopian tube cancer	0.0102	0.0102	CbGeAlD
Nilotinib—MAPK8—vagina—fallopian tube cancer	0.0102	0.0102	CbGeAlD
Nilotinib—TIE1—female reproductive system—fallopian tube cancer	0.00974	0.00974	CbGeAlD
Nilotinib—MAPK14—epithelium—fallopian tube cancer	0.0096	0.0096	CbGeAlD
Nilotinib—MAPK14—uterine cervix—fallopian tube cancer	0.00952	0.00952	CbGeAlD
Nilotinib—LCK—uterine cervix—fallopian tube cancer	0.00948	0.00948	CbGeAlD
Nilotinib—HCK—uterus—fallopian tube cancer	0.00947	0.00947	CbGeAlD
Nilotinib—EPHB3—female reproductive system—fallopian tube cancer	0.00926	0.00926	CbGeAlD
Nilotinib—MAP4K1—vagina—fallopian tube cancer	0.00923	0.00923	CbGeAlD
Nilotinib—EPHB4—epithelium—fallopian tube cancer	0.0091	0.0091	CbGeAlD
Nilotinib—EPHB4—uterine cervix—fallopian tube cancer	0.00903	0.00903	CbGeAlD
Nilotinib—EPHA2—epithelium—fallopian tube cancer	0.00893	0.00893	CbGeAlD
Nilotinib—TIE1—female gonad—fallopian tube cancer	0.00886	0.00886	CbGeAlD
Nilotinib—EPHA2—uterine cervix—fallopian tube cancer	0.00885	0.00885	CbGeAlD
Nilotinib—TEK—epithelium—fallopian tube cancer	0.00871	0.00871	CbGeAlD
Nilotinib—EPHA4—uterus—fallopian tube cancer	0.00861	0.00861	CbGeAlD
Nilotinib—FGR—endometrium—fallopian tube cancer	0.00858	0.00858	CbGeAlD
Nilotinib—CA3—uterus—fallopian tube cancer	0.0085	0.0085	CbGeAlD
Nilotinib—BRAF—female gonad—fallopian tube cancer	0.0085	0.0085	CbGeAlD
Nilotinib—BRAF—vagina—fallopian tube cancer	0.00844	0.00844	CbGeAlD
Nilotinib—EPHB3—female gonad—fallopian tube cancer	0.00843	0.00843	CbGeAlD
Nilotinib—EPHB3—vagina—fallopian tube cancer	0.00838	0.00838	CbGeAlD
Nilotinib—EPHB6—uterine cervix—fallopian tube cancer	0.00826	0.00826	CbGeAlD
Nilotinib—EPHB4—endometrium—fallopian tube cancer	0.00816	0.00816	CbGeAlD
Nilotinib—EPHA2—endometrium—fallopian tube cancer	0.00801	0.00801	CbGeAlD
Nilotinib—MAPK14—uterus—fallopian tube cancer	0.00794	0.00794	CbGeAlD
Nilotinib—LCK—uterus—fallopian tube cancer	0.0079	0.0079	CbGeAlD
Nilotinib—TEK—endometrium—fallopian tube cancer	0.00781	0.00781	CbGeAlD
Nilotinib—HCK—female gonad—fallopian tube cancer	0.00775	0.00775	CbGeAlD
Nilotinib—EPHA4—female reproductive system—fallopian tube cancer	0.00774	0.00774	CbGeAlD
Nilotinib—HCK—vagina—fallopian tube cancer	0.0077	0.0077	CbGeAlD
Nilotinib—ABL2—female gonad—fallopian tube cancer	0.0077	0.0077	CbGeAlD
Nilotinib—ABL2—vagina—fallopian tube cancer	0.00765	0.00765	CbGeAlD
Nilotinib—EPHB4—uterus—fallopian tube cancer	0.00752	0.00752	CbGeAlD
Nilotinib—EPHB6—endometrium—fallopian tube cancer	0.00747	0.00747	CbGeAlD
Nilotinib—CA9—female reproductive system—fallopian tube cancer	0.00732	0.00732	CbGeAlD
Nilotinib—TEK—uterus—fallopian tube cancer	0.0072	0.0072	CbGeAlD
Nilotinib—MAPK14—female reproductive system—fallopian tube cancer	0.00713	0.00713	CbGeAlD
Nilotinib—FGR—female reproductive system—fallopian tube cancer	0.0071	0.0071	CbGeAlD
Nilotinib—MAP2K5—uterine cervix—fallopian tube cancer	0.00706	0.00706	CbGeAlD
Nilotinib—EPHA4—female gonad—fallopian tube cancer	0.00704	0.00704	CbGeAlD
Nilotinib—EPHA4—vagina—fallopian tube cancer	0.007	0.007	CbGeAlD
Nilotinib—CA3—vagina—fallopian tube cancer	0.00691	0.00691	CbGeAlD
Nilotinib—CSF1R—uterine cervix—fallopian tube cancer	0.00689	0.00689	CbGeAlD
Nilotinib—EPHB4—female reproductive system—fallopian tube cancer	0.00676	0.00676	CbGeAlD
Nilotinib—EPHA2—female reproductive system—fallopian tube cancer	0.00663	0.00663	CbGeAlD
Nilotinib—PDGFRA—uterus—fallopian tube cancer	0.00652	0.00652	CbGeAlD
Nilotinib—MAPK14—female gonad—fallopian tube cancer	0.00649	0.00649	CbGeAlD
Nilotinib—TEK—female reproductive system—fallopian tube cancer	0.00647	0.00647	CbGeAlD
Nilotinib—LCK—female gonad—fallopian tube cancer	0.00646	0.00646	CbGeAlD
Nilotinib—FGR—female gonad—fallopian tube cancer	0.00646	0.00646	CbGeAlD
Nilotinib—MAPK14—vagina—fallopian tube cancer	0.00645	0.00645	CbGeAlD
Nilotinib—FGR—vagina—fallopian tube cancer	0.00643	0.00643	CbGeAlD
Nilotinib—LCK—vagina—fallopian tube cancer	0.00643	0.00643	CbGeAlD
Nilotinib—MAP2K5—endometrium—fallopian tube cancer	0.00639	0.00639	CbGeAlD
Nilotinib—KIT—epithelium—fallopian tube cancer	0.00631	0.00631	CbGeAlD
Nilotinib—KIT—uterine cervix—fallopian tube cancer	0.00626	0.00626	CbGeAlD
Nilotinib—CSF1R—endometrium—fallopian tube cancer	0.00623	0.00623	CbGeAlD
Nilotinib—PDGFRB—epithelium—fallopian tube cancer	0.00616	0.00616	CbGeAlD
Nilotinib—EPHB4—female gonad—fallopian tube cancer	0.00615	0.00615	CbGeAlD
Nilotinib—EPHB4—vagina—fallopian tube cancer	0.00612	0.00612	CbGeAlD
Nilotinib—PDGFRB—uterine cervix—fallopian tube cancer	0.00611	0.00611	CbGeAlD
Nilotinib—EPHA2—female gonad—fallopian tube cancer	0.00604	0.00604	CbGeAlD
Nilotinib—EPHA2—vagina—fallopian tube cancer	0.006	0.006	CbGeAlD
Nilotinib—TEK—female gonad—fallopian tube cancer	0.00589	0.00589	CbGeAlD
Nilotinib—PDGFRA—female reproductive system—fallopian tube cancer	0.00586	0.00586	CbGeAlD
Nilotinib—CSF1R—uterus—fallopian tube cancer	0.00574	0.00574	CbGeAlD
Nilotinib—KIT—endometrium—fallopian tube cancer	0.00566	0.00566	CbGeAlD
Nilotinib—EPHB6—female gonad—fallopian tube cancer	0.00563	0.00563	CbGeAlD
Nilotinib—EPHB6—vagina—fallopian tube cancer	0.00559	0.00559	CbGeAlD
Nilotinib—PDGFRB—endometrium—fallopian tube cancer	0.00553	0.00553	CbGeAlD
Nilotinib—ABL1—uterine cervix—fallopian tube cancer	0.00545	0.00545	CbGeAlD
Nilotinib—CA12—female reproductive system—fallopian tube cancer	0.00541	0.00541	CbGeAlD
Nilotinib—PDGFRA—female gonad—fallopian tube cancer	0.00534	0.00534	CbGeAlD
Nilotinib—PDGFRA—vagina—fallopian tube cancer	0.0053	0.0053	CbGeAlD
Nilotinib—MAP2K5—female reproductive system—fallopian tube cancer	0.00529	0.00529	CbGeAlD
Nilotinib—KIT—uterus—fallopian tube cancer	0.00521	0.00521	CbGeAlD
Nilotinib—CSF1R—female reproductive system—fallopian tube cancer	0.00516	0.00516	CbGeAlD
Nilotinib—PDGFRB—uterus—fallopian tube cancer	0.00509	0.00509	CbGeAlD
Nilotinib—ABL1—endometrium—fallopian tube cancer	0.00493	0.00493	CbGeAlD
Nilotinib—MAP2K5—female gonad—fallopian tube cancer	0.00481	0.00481	CbGeAlD
Nilotinib—MAP2K5—vagina—fallopian tube cancer	0.00478	0.00478	CbGeAlD
Nilotinib—CSF1R—female gonad—fallopian tube cancer	0.0047	0.0047	CbGeAlD
Nilotinib—KIT—female reproductive system—fallopian tube cancer	0.00469	0.00469	CbGeAlD
Nilotinib—CSF1R—vagina—fallopian tube cancer	0.00467	0.00467	CbGeAlD
Nilotinib—PDGFRB—female reproductive system—fallopian tube cancer	0.00458	0.00458	CbGeAlD
Nilotinib—ABL1—uterus—fallopian tube cancer	0.00454	0.00454	CbGeAlD
Nilotinib—CA1—female reproductive system—fallopian tube cancer	0.00429	0.00429	CbGeAlD
Nilotinib—KIT—female gonad—fallopian tube cancer	0.00427	0.00427	CbGeAlD
Nilotinib—KIT—vagina—fallopian tube cancer	0.00424	0.00424	CbGeAlD
Nilotinib—PDGFRB—female gonad—fallopian tube cancer	0.00417	0.00417	CbGeAlD
Nilotinib—PDGFRB—vagina—fallopian tube cancer	0.00414	0.00414	CbGeAlD
Nilotinib—ABL1—female reproductive system—fallopian tube cancer	0.00408	0.00408	CbGeAlD
Nilotinib—CA2—epithelium—fallopian tube cancer	0.00374	0.00374	CbGeAlD
Nilotinib—ABL1—female gonad—fallopian tube cancer	0.00371	0.00371	CbGeAlD
Nilotinib—ABL1—vagina—fallopian tube cancer	0.00369	0.00369	CbGeAlD
Nilotinib—ABCG2—uterine cervix—fallopian tube cancer	0.00343	0.00343	CbGeAlD
Nilotinib—CA4—female reproductive system—fallopian tube cancer	0.00335	0.00335	CbGeAlD
Nilotinib—CYP2C8—endometrium—fallopian tube cancer	0.00319	0.00319	CbGeAlD
Nilotinib—ABCG2—endometrium—fallopian tube cancer	0.00311	0.00311	CbGeAlD
Nilotinib—CA4—female gonad—fallopian tube cancer	0.00305	0.00305	CbGeAlD
Nilotinib—ABCG2—uterus—fallopian tube cancer	0.00286	0.00286	CbGeAlD
Nilotinib—CA2—female reproductive system—fallopian tube cancer	0.00278	0.00278	CbGeAlD
Nilotinib—CYP2C8—female reproductive system—fallopian tube cancer	0.00265	0.00265	CbGeAlD
Nilotinib—CA2—female gonad—fallopian tube cancer	0.00253	0.00253	CbGeAlD
Nilotinib—CA2—vagina—fallopian tube cancer	0.00251	0.00251	CbGeAlD
Nilotinib—CYP2C8—vagina—fallopian tube cancer	0.00239	0.00239	CbGeAlD
Nilotinib—CYP2B6—female reproductive system—fallopian tube cancer	0.00237	0.00237	CbGeAlD
Nilotinib—CYP2C9—female reproductive system—fallopian tube cancer	0.00235	0.00235	CbGeAlD
Nilotinib—ABCG2—female gonad—fallopian tube cancer	0.00234	0.00234	CbGeAlD
Nilotinib—ABCG2—vagina—fallopian tube cancer	0.00233	0.00233	CbGeAlD
Nilotinib—CYP2B6—vagina—fallopian tube cancer	0.00215	0.00215	CbGeAlD
Nilotinib—CYP3A4—female reproductive system—fallopian tube cancer	0.00179	0.00179	CbGeAlD
Nilotinib—CYP2D6—female reproductive system—fallopian tube cancer	0.00176	0.00176	CbGeAlD
Nilotinib—ABCB1—epithelium—fallopian tube cancer	0.00171	0.00171	CbGeAlD
Nilotinib—ABCB1—uterine cervix—fallopian tube cancer	0.00169	0.00169	CbGeAlD
Nilotinib—CYP2D6—female gonad—fallopian tube cancer	0.00161	0.00161	CbGeAlD
Nilotinib—ABCB1—endometrium—fallopian tube cancer	0.00153	0.00153	CbGeAlD
Nilotinib—ABCB1—uterus—fallopian tube cancer	0.00141	0.00141	CbGeAlD
Nilotinib—ABCB1—female reproductive system—fallopian tube cancer	0.00127	0.00127	CbGeAlD
Nilotinib—ABCB1—female gonad—fallopian tube cancer	0.00115	0.00115	CbGeAlD
Nilotinib—ABCB1—vagina—fallopian tube cancer	0.00115	0.00115	CbGeAlD
